Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.
To assess the effects of antifungal therapy on the course of Candida albicans central nervous system infection and inflammation, we inoculated intracisternally 10(5) CFU of C. albicans into rabbits. Fluconazole (10 mg/kg of body weight) or amphotericin B (1 mg/kg) was infused intravenously daily for 14 days. Treatment was initiated 24 h or 5 days after infection. Cerebrospinal fluid (CSF) was repeatedly obtained to culture the organisms, assess the level of inflammation, and measure drug concentrations. Brain tissue was obtained at the end of therapy for culture, drug concentration determinations, and histopathology. The median number of days of treatment required to sterilize CSF cultures was 4 days for fluconazole therapy and 1 day for amphotericin B therapy (P = 0.037). There was a significant reduction in tumor necrosis factor alpha and leukocyte concentrations in the CSF of animals treated early versus those in untreated control animals (P < 0.05 and P < 0.001, respectively; analysis of variance). Compared with treated animals, a higher proportion of cultured CSF samples from untreated animals were positive for Candida (P < 0.001). A cultured brain sample from 1 of the 12 animals treated early with amphotericin B was positive for C. albicans (P < 0.01 versus controls); cultures of brain samples from 3 of 12 animals treated early with fluconazole were positive, whereas cultures of brain samples from 10 of 12 controls were positive (P < 0.05). The mean density of C. albicans was lower in the single culture-positive amphotericin B recipient (1 x 10(1) CFU/g of brain tissue) than in those treated with fluconazole (1 x 10(3) CFU/g) and in controls (8 x 10(4) CFU/g). In animals treated late, the density of C. albicans in the brain in relation to the number of days of therapy was significantly lower in amphotericin B recipients than in those treated with fluconazole (P < 0.01) and untreated controls (P < 0.01; analysis of covariance). By histopathology, a larger proportion of untreated animals compared with those treated early demonstrated features of severe infection such as perivasculitis, ventriculitis, and evidence of fungal organisms. Compared with amphotericin B-treated rabbits, those given fluconazole had a trend toward more severe pathologic lesions. Reduced susceptibility to both fluconazole and amphotericin B was observed in the C. albicans organisms isolated from the brain of one fluconazole-treated animal. These data suggest that amphotericin B is the preferred treatment for C. albicans infections of the central nervous system.
Jafari
H S
HS
Department of Pediatrics, University of Texas Southwestern Medical Center at Dallas 75235-9063, USA.
Sáez-Llorens
X
X
Severien
C
C
Parras
F
F
Friedland
I
I
Rinderknecht
S
S
Ehrett
S
S
Olsen
K D
KD
Abramowsky
C
C
McCracken
G H
GH
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D002176:Candida albicans / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D016207:Cytokines / Q000134:cerebrospinal fluid; D015725:Fluconazole / Q000627:therapeutic use; D007249:Inflammation / Q000473:pathology; D007372:Interferons / Q000097:blood; D007958:Leukocyte Count; D008297:Male; D016921:Meningitis, Fungal / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D014409:Tumor Necrosis Factor-alpha / Q000134:cerebrospinal fluid
D000935:Antifungal Agents; D016207:Cytokines; D014409:Tumor Necrosis Factor-alpha; D000666:Amphotericin B; D015725:Fluconazole; D007372:Interferons